Mondher Mahjoubi

Mondher joined the Executive Committee in 2026. As Chief Patient Officer he leads the development and execution of GSK’s global medical strategy, ensuring the scientific integrity and clinical value of GSK’s medicines and vaccines worldwide. He oversees medical governance, evidence generation, and scientific engagement. He joined GSK in 2024. 

Before joining GSK, Mondher was CEO of Innate Pharma, and held senior leadership roles at AstraZeneca, Genentech, Roche, and Sanofi. 

Mondher holds an MD from the University of Tunis and completed his medical oncology training at Institut Gustave Roussy and the University of Paris Sud.